Roth Capital Issues Pessimistic Forecast for TENX Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Roth Capital dropped their Q2 2025 earnings per share estimates for shares of Tenax Therapeutics in a research note issued on Wednesday, May 14th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings of ($0.19) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.96) EPS.

A number of other equities research analysts have also issued reports on TENX. Guggenheim restated a “buy” rating and issued a $15.00 target price on shares of Tenax Therapeutics in a research note on Thursday. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a report on Monday, March 10th. StockNews.com assumed coverage on Tenax Therapeutics in a report on Friday. They set a “sell” rating on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Tenax Therapeutics Price Performance

NASDAQ TENX opened at $6.02 on Monday. The company has a market capitalization of $24.97 million, a price-to-earnings ratio of -2.43 and a beta of 1.92. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.89. The company’s fifty day moving average price is $5.85 and its two-hundred day moving average price is $5.93.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20.

Institutional Investors Weigh In On Tenax Therapeutics

A number of institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC acquired a new stake in Tenax Therapeutics during the fourth quarter worth about $1,026,000. ADAR1 Capital Management LLC grew its holdings in shares of Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after purchasing an additional 34,048 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Tenax Therapeutics during the 4th quarter worth approximately $166,000. Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics in the 4th quarter worth approximately $84,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the last quarter. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.